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Abstract
Background: Prediction of the outcome of sorafenib therapy using biomarkers is an unmet clinical need in
patients with advanced hepatocellular carcinoma (HCC). The aim was to develop and validate a biomarker-based
model for predicting sorafenib response and overall survival (OS).
Methods: This prospective cohort study included 124 consecutive HCC patients (44 with disease control, 80 with
progression) with Child-Pugh class A liver function, who received sorafenib. Potential serum biomarkers (namely,
hepatocyte growth factor [HGF], fibroblast growth factor [FGF], vascular endothelial growth factor receptor-1,
CD117, and angiopoietin-2) were tested. After identifying independent predictors of tumor response, a risk scoring
system for predicting OS was developed and 3-fold internal validation was conducted.
Results: A risk scoring system was developed with six covariates: etiology, platelet count, Barcelona Clinic Liver Cancer
stage, protein induced by vitamin K absence-II, HGF, and FGF. When patients were stratified into low-risk (score≤ 5),
intermediate-risk (score 6), and high-risk (score≥ 7) groups, the model provided good discriminant functions on tumor
response (concordance [c]-index, 0.884) and 12-month survival (area under the curve [AUC], 0.825). The median OS was
19.0, 11.2, and 6.1 months in the low-, intermediate-, and high-risk group, respectively (P < 0.001). In internal validation,
the model maintained good discriminant functions on tumor response (c-index, 0.825) and 12-month survival (AUC, 0.
803), and good calibration functions (all P > 0.05 between expected and observed values).
Conclusions: This new model including serum FGF and HGF showed good performance in predicting the response to
sorafenib and survival in patients with advanced HCC.
Keywords: Hepatocellular carcinoma, Sorafenib, Response, Biomarker, Prediction
* Correspondence: pindra@empal.com; JHLeeMD@gmail.com
* The abstract of the present study was presented as a poster at the Liver
Meeting 2016 (the 67th Annual Meeting of the American Association for the
Study of Liver Diseases) (Kim HY, Lee DH, Cho EJ, Yu SJ, Kim YJ, Yoon J-H,
Lee J-H: A Novel Biomarker-Based Model for the Prediction of Response to
Sorafenib and Overall Survival for Advanced Hepatocellular Carcinoma: A
Prospective Cohort Study. In: HEPATOLOGY: 2016: WILEY 111 RIVER ST,
HOBOKEN 07030–5774, NJ USA; 2016: 634A-634A.).
†Equal contributors
2Department of Internal Medicine and Liver Research Institute, Seoul
National University College of Medicine, Seoul, Republic of Korea
4Department of Internal Medicine, Seoul National University Hospital, 101,
Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kim et al. BMC Cancer  (2018) 18:307 
https://doi.org/10.1186/s12885-018-4211-2
Background
Sorafenib is an oral multikinase inhibitor targeting the
receptor tyrosine kinase activity of VEGF receptors
(VEGFR 1–3), PDGFRb, serine-threonine kinases Raf-1
and B-Raf, c-KIT, and RET [1–3]. Sorafenib therapy pro-
longed overall survival (OS) with acceptable safety and
tolerability in patients with advanced HCC in the
SHARP (Sorafenib Hepatocellular Carcinoma Assess-
ment Randomized Protocol) trial and the Asia-Pacific
study [4, 5]. Based on these two phase III trials, sorafe-
nib therapy is currently the standard of care for patients
with advanced-stage or Barcelona Clinic Liver Cancer
(BCLC) stage C HCC and for patients in the control
arm of ongoing clinical trials [6, 7]. However, consider-
ing the various adverse effects, incomplete response,
modest survival benefit and cost of sorafenib therapy,
the necessity of predictive biomarkers has been con-
stantly raised, to select patients who could benefit most
from this treatment [8].
Cancer biomarkers have been widely used for the predic-
tion of the natural course, prognosis, and treatment
response in certain malignancies [9]. Predictive biomarkers
can be best explored in the setting of properly designed
clinical trials [10]. Baseline plasma angiopoietin 2 and vas-
cular endothelial growth factor (VEGF) were identified as
independent predictors of survival in the SHARP study;
however, no biomarker was predictive of sorafenibresponse
[11]. Because the diagnosis of HCC is usually made without
obtaining tumor tissue, serum biomarkers for the predic-
tion of sorafenib response would be of significant benefit
for proper selection of patients [12]. Furthermore, there has
been no attempt to date to integrate potential serum
markers and other relevant clinical characteristics for a
response prediction model as an approach toward precision
medicine in patients with advanced HCC.
This exploratory study aimed (i) to develop a novel
relevant predictive model using a serum biomarker for
the prediction of sorafenib response, (ii) to validate this
model internally, and (iii) to determine its role in pre-
dicting outcome in a prospectively collected database
from a large-scale in-hospital cohort.Specifically, we
chose analytes for serum biomarker analysis on the basis
of the molecular targets (or ligands of those targeted
receptors) of sorafenib or those related to the outcome
and/or pathogenesis of HCC, including VEGF [11],
platelet-derived growth factor receptor β (PDGFRb) [2],
CD117 [1], hepatocyte growth factor (HGF) [13], angio-
poietin 2 [11], lysyl oxidase-like 2 (LOXL2) [14], and
basic fibroblast growth factor (bFGF) [15].
Methods
Patients
Between May 2013 and June 2015, a total of 460 con-
secutive patients who had a diagnosis of HCC and
received sorafenib were identified in a prospective HCC
cohort registry of Seoul National University Hospital.
Written informed consent was obtained from each pa-
tient before registration in the cohort. The diagnosis of
HCC was based on histological examination or clinico-
radiological criteria, with reference to the practice guide-
lines from the American Association for the Study of
Liver Diseases or the European Association for the Study
of the Liver [6, 7]. All patients were not indicated for
surgical resection, liver transplantation, local ablation, or
transarterial chemoembolization at the time of initiation
of sorafenib therapy because of their advanced stages at
the time of diagnosis or tumor progression despite prior
(repeated) locoregional treatments. Among these 460 pa-
tients, adequate blood samples were obtained from 161
patients for serum biomarker analyses. Patients with
Child-Pugh score ≥ 7 (n = 37) were excluded because the
outcome assessment of sorafenib therapy in these pa-
tients could be misleading, owing to increased risk of
mortality from their impaired liver function [16]. Finally,
124 patients were included in the analysis.
The protocol of the present study conformed to the
ethical guidelines of the World Medical Association
Declaration of Helsinki, and was approved by the Institu-
tional Review Board of Seoul National University Hospital
(IRB No. 0506–150-005). All study participants provided
written informed consent. REMARK (Reporting Recom-
mendations for Tumor Marker Prognostic Studies) cri-
teria were followed throughout this study [17].
Treatment scheme and response evaluation
The standard daily oral dose of sorafenib (Nexavar;
Bayer HealthCare AG, Leverkusen, Germany) was
800 mg (i.e., 400 mg twice daily) on a continuous dosing
schedule. Follow-up evaluation schedules included (i)
clinical examination (toxicity assessment and blood
tests) 2 weeks after the first administration of sorafenib
and every 4 weeks thereafter, and (ii) imaging tests (con-
trast-enhanced dynamic computed tomography or mag-
netic resonance imaging) every 6–8 weeks until death or
the last follow-up. Dose reduction was allowed in cases
of drug-related grade 3 or 4 toxicities. The toxicity grade
was assessed before each treatment cycle using the
National Cancer Institute Common Toxicity Criteria for
Adverse Events (version 4.0). We used three-step dose
reduction as follows: 800 mg daily to 600 mg daily,
600 mg daily to 400 mg daily, and 400 mg daily to
400 mg every other day. Treatment response was evalu-
ated every 6–8 weeks, according to the modified
Response Evaluation Criteria in Solid Tumors criteria
using contrast-enhanced dynamic computed tomography
or magnetic resonance imaging [18]. Sorafenib therapy
was discontinued if one or more of the following
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occurred: disease progression, development of intoler-
able toxicity, or patient refusal.
Sample collection and biomarker assays
A 5-mL blood sample was collected from each study
participant at baseline (before the initiation of sorafenib
therapy), and was centrifuged at 1500 rpm for 15 min to
separate the serum. The serum samples were then stored
at ≤ − 70 °C in 1.5-mL aliquots until further assays.
The serum concentrations of biomarkers were mea-
sured with commercially available ELISA kits for angio-
poietin 2 (R&D Systems, Minneapolis, MN, USA), VEGF
(eBioscience, San Diego, CA, USA), PDGFRb (Raybiotech,
Norcross, GA, USA), HGF (R&D Systems), CD117 (R&D
Systems), LOXL2 (USCN Life Science, Wuhan, China),
and bFGF (R&D Systems).
Statistical analysis
For baseline characteristics, continuous variables are
expressed as medians and ranges, and categorical vari-
ables as frequencies with percentages. Survival analysis
was performed using the Kaplan-Meier method from the
date of initial diagnosis of HCC to the date of death or
last follow-up, with the log-rank test to compare sub-
groups. Single binary logistic regression analysis was
used to identify relevant features associated with re-
sponse to sorafenib, in which variables with P < 0.1 were
subsequently included in the multivariate analysis. The
selected variables for logistic regression analysis included
clinical characteristics, laboratory parameters, serum
biomarkers, and hepatic fibrosis indices [19–22]. For-
ward and backward stepwise selection procedures were
sequentially used to select the best-fitted model on the
basis of the Akaike information criterion [23]. In the
final model, scores (0, 1, 2) were assigned to the corre-
sponding levels of categorical covariates. For continuous
covariates, scores were assigned to the corresponding
subranges within cutoff values, to maximize the con-
cordance index (c-index). Hence, the risk score for the
prediction of sorafenib response was calculated in each
patient through the summation of the scores of the
covariates in the final prediction model. Patients were
further categorized into subgroups according to their
predictive scores. For an internal validation of the pre-
dictive model, a 3-fold cross-validation was performed.
Calibration function was examined by comparing the
observed response with the expected response estimated
with the risk score, using the Hosmer-Lemeshow test. In
addition, survival prediction was performed among sub-
groups according to the risk scores, with internal valid-
ation and examination of calibration function, in the
same manner as that for the response prediction.
All tests were based on a two-sided probability, and
P < 0.05 was considered statistically significant. All
statistical analyses were performed with R language
ver. 3.1.1 (R Foundation for Statistical Computing,
Vienna, Austria).
Results
Patient characteristics and treatment outcomes
Table 1 summarizes the baseline characteristics of the
enrolled patients according to their best objective
responses to sorafenib, i.e., progressive disease (PD) vs.
non-PD. During the treatment period (median,
2.6 months; interquartile range, 1.4–3.8 months), 44
patients had no disease progression (non-PD group:
complete response, 2 patients; partial response, 10
patients; and stable disease, 32 patients) and 80 patients
had disease progression (PD group). The median time to
progression was 2.7 months (95% confidence interval
[CI], 2.4–3.1). The main underlying cause of liver disease
was hepatitis B infection (59.1% in the non-PD group,
81.2% in the PD group). There was no significant differ-
ence in the frequencies of macrovascular invasion or
extrahepatic spread and baseline Child-Pugh score between
the two groups. Platelet count was significantly lower in the
PD group than in the non-PD group (P = 0.006). Of the
baseline tumor markers, PIVKA-II (protein induced by
vitamin K absence-II) was significantly higher in the PD
group than in the non-PD group (P = 0.003), unlike alpha-
fetoprotein (P = 0.187). Among the serum biomarkers, only
bFGF was significantly higher in the PD group than in the
non-PD group (P < 0.001).
The median follow-up duration was 6.6 months (inter-
quartile range, 4.3–12.1 months) and OS was 11.2 months
(95% CI, 9.4–13.7).
Development of a scoring system for the prediction of
sorafenib response
From the single binary logistic regression analysis,
variables with P < 0.1 were first selected for multivariate
analysis, including etiology, platelet count, PIVKA-II,
bFGF, macrovascular invasion, extrahepatic spread,
BCLC stage, and log HGF (Table 2). Among these
variables, multivariate logistic regression analysis with
forward stepwise selection process identified six vari-
ables for the final model (Table 2), which included four
tumor-related factors (BCLC stage, bFGF, log PIVKA-II,
and log HGF) and two liver disease-related factors
(etiology and platelets). The risk scoring system for the
prediction of sorafenib response was generated using
these six covariates, in which a score of 0, 1, or 2 was
given to each cutoff value of the six covariates (Table 3).
The risk score for each patient was calculated through
the summation of the scores of the six covariates, and
the scores ranged from 0 to 12. Sorafenib response was
expected to be PD if the risk score was > 6, showing
maximal sensitivity and specificity with this cutoff level
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(Fig. 1). When all patients were stratified into the low-risk
group (risk score ≤ 5; n = 43), intermediate-risk group (risk
score 6, n = 24), and high-risk group (risk score ≥ 7, n = 57),
the model provided good discriminant functions on sorafe-
nib response (c-index, 0.884; 95% CI, 0.827–0.941). In the
internal validation with 3-fold cross-validation, the model
maintained good discriminant functions on tumor response
(c-index, 0.825; 95% CI, 0.745–0.906), and the Hosmer-
Lemeshow P-value for the calibration function of the risk
score was 0.945.
Effect of the sorafenib response score on the OS
Median OS duration was 19.0 months in the low-risk
group (95% CI, 16.1–not available [N/A]), 11.2 months
Table 1 Baseline characteristics according to the sorafenib response
Variable All (n = 124) Non-PD (n = 44) PD (n = 80) P
Age (year) 61 ± 11 62 ± 10 61 ± 12 0.707
Sex, N (%) 107 (86.3) 36 (81.8) 71 (88.8) 0.423
ECOG performance status 0, N (%) 112 (90.3) 42 (95.5) 70 (87.5) 0.210
Etiology, N (%) 0.02
HBV 91 (73.4) 26 (59.1) 65 (81.2)
HCV 21 (16.9) 10 (22.7) 11 (13.8)
Alcohol 12 (9.7) 8 (18.2) 4 (5)
Body mass index (kg/m2) 22.3 ± 3.1 23.1 ± 3.2 21.9 ± 3.0 0.052
Macrovascular invasion, N (%) 39 (31.5) 11 (25.0) 28 (35.0) 0.344
Extrahepatic spread, N (%) 53 (42.7%) 16 (36.4) 37 (46.2) 0.382
BCLC stage C, N (%) 83 (66.9%) 25 (56.8) 58 (72.5) 0.185
Child-Pugh score, N (%) 0.492
5 114 (91.9) 42 (95.5) 72 (90)
6 10 (8.1) 2 (4.5) 8 (10)
MELD 8.8 ± 2.2 8.36 ± 1.54 8.96 ± 2.47 0.1
Albumin (g/dL) 3.79 ± 0.42 3.78 ± 0.46 3.81 ± 0.41 0.739
Total bilirubin (mg/dL) 1.06 ± 0.50 0.99 ± 0.47 1.09 ± 0.51 0.273
Prothrombin time (INR) 1.14 ± 0.10 1.13 ± 0.09 1.15 ± 0.1 0.299
Creatinine (mg/dL) 0.89 ± 0.56 0.87 ± 0.13 0.9 ± 0.69 0.705
Platelet (×103/μL) 122 (17–787) 113 (17–291) 128 (52–787) 0.006
Alpha-fetoprotein (ng/mL) 128.8 (1.3–730,000) 114.7 (2.6–226,100) 152.2 (1.3–730,000) 0.187
PIVKA-II (mAU/mL) 109.5 (12–339,858) 25.5 (12–25,884) 351 (15–339,858) 0.003
Angiopoietin 2 (ng/mL) 2962.7 (1099.4–12,907.8) 2762.2 (1289.6–8360.4) 3026.9 (1099.4–12,907.8) 0.109
CD117 (ng/mL) 3.76 (1.01–226.85) 3.36 (1.01–10.23) 3.87 (1.10–226.85) 0.234
bFGF (pg/mL) 2.38 (0–61.57) 1.65 (0–14.62) 3.07 (0.43–61.57) < 0.001
HGF (pg/mL) 1781.9 (913.9–6116.0) 1605.7 (913.9–4152.4) 1965.2 (1020.3–6117.0) 0.056
LOXL2 (ng/mL) 0.816 (0.034–4.007) 0.718 (0.034–4.007) 0.850 (0.039–3.765) 0.792
PDGFRb (pg/mL) 2045.6 (647.5–22,904.5) 2087.9 (777.7–22,904.5) 1965.3 (647.5–8214.9) 0.419
sVEGFR1 (ng/mL) 0.16 (0.04–13.65) 0.16 (0.06–13.65) 0.14 (0.04–0.53) 0.314
AAR 1.29 (0.58–11.6) 1.31 (0.58–2.67) 1.29 (0.61–11.6) 0.105
APRI 1.01 (0.17–6.54) 1.17 (0.17–4.54) 0.95 (0.17–6.54) 0.847
FIB-4 4.0 (0.6–21.0) 4.4 (0.9–21.0) 3.6 (0.6–12.3) 0.161
Lok index 0.66 ± 0.24 0.67 ± 0.24 0.65 ± 0.24 0.68
P2/MS 29.6 (0.46–1060.7) 27.3 (0.5–202.4) 36.7 (6.2–1060.7) 0.102
Values are expressed as mean ± standard deviation, medians (ranges), or frequencies (percentages)
Abbreviations: PD, progressive disease, ECOG Eastern Cooperative Oncology Group, HBV hepatitis B virus, HCV hepatitis C virus, BCLC Barcelona Clinic Liver Cancer,
MELD model for end-stage liver disease, INR international normalized ratio, PIVKA-II protein induced by vitamin K absence-II, Ang2 angiopoietin-2, bFGF basic
fibroblast growth factor, HGF hepatocyte growth factor, LOXL2 lysyl oxidase-like 2, PDGFRb platelet-derived growth factor receptor β, sVEGFR1 soluble vascular
endothelial growth factor receptor-1, AAR aspartate aminotransferase/alanine aminotransferase ratio, APRI aspartate aminotransferase to platelet ratio index, FIB-4 fibrosis 4
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in the intermediate-risk group (95% CI, 8.5–N/A),
and 6.1 months in the high-risk group (95% CI, 5.0–8.1)
(P < 0.001, Fig. 2). Univariate Cox proportional haz-
ards analysis with the above-mentioned risk scoring
system showed a significant difference between group
A and group C (P < 0.001, Table 4). The area under
the receiver-operating curve for OS prediction was
0.825 (95% CI, 0.734–0.915) at 12 months. In the in-
ternal validation with 3-fold cross-validation, the area
under the receiver-operating curve for OS prediction
at 12 months was 0.803 (95% CI, 0.699–0.907). The
Hosmer-Lemeshow P-value for the calibration func-
tion of the risk score was 0.207.
Discussion
We developed a new prediction model for sorafenib
response that combines relevant serum markers, tumor-
related factors, and cirrhosis-related factors in a scoring
system. The risk score showed good performance in pre-
dicting the response to sorafenib and survival in patients
with advanced HCC in our cohort. The robustness of
Table 2 Binary logistic regression analysis for sorafenib response
Variable Univariate analysis Multivariate analysis
OR (95% CI) P OR (95% CI) P
Age (year) 0.994 (0.963–1.027) 0.719
Sex (Female) 0.570 (0.203–1.603) 0.287
Body mass index (kg/m2) 0.885 (0.783–1.000) 0.050
ECOG PS (1 vs. 0) 3.000 (0.627–14.358) 0.169
Etiology HCV vs. nonviral 0.440 (0.167–1.16) 0.097 0.612 (0.179–2.088) 0.433
HBV vs. nonviral 0.200 (0.055–0.722) 0.014 0.133 (0.027–0.666) 0.014
Ascites 2 vs. 1 2.333 (0.473–11.506) 0.298
Platelet (×103/μL) 1.006 (1.001–1.011) 0.017 1.005 (0.999–1.011) 0.103
Creatinine (mg/dL) 1.115 (0.529–2.348) 0.775
Albumin (g/dL) 1.168 (0.488–2.794) 0.727
Total bilirubin (mg/dL) 1.541 (0.698–3.405) 0.285
Prothrombin time (INR) 6.922 (0.164–291.871) 0.311
MELD 1.208 (0.937–1.558) 0.145
Macrovascular invasion 1.615 (0.71–3.677) 0.253
Extrahepatic spread 1.506 (0.708–3.205) 0.288
BCLC stage B vs. A 1.000 (0.315–3.174) 1.000 0.808 (0.203–3.224) 0.763
C vs. A 2.895 (1.002–8.364) 0.050 3.476 (0.987–12.243) 0.052
Log AFP (ng/dL) 1.013 (0.779–1.317) 0.925
Log PIVKA-II (mAU/mL) 1.989 (1.359–2.911) < 0.001 1.724 (1.124–2.644) 0.013
Log Angiopoietin 2 (ng/mL) 3.754 (0.534–26.374) 0.183
Log CD117 (ng/mL) 2.895 (0.612–13.687) 0.18
bFGF (pg/mL) 1.321 (1.092–1.598) 0.004 1.326 (1.077–1.634) 0.008
Log HGF (pg/mL) 16.534 (1.275–214.349) 0.032 23.438 (0.750–732.109) 0.072
LOXL2 (ng/mL) 0.769 (0.533–1.11) 0.160
Log sVEGFR1 (ng/mL) 0.272 (0.047–1.592) 0.149
AAR 1.373 (0.84–2.246) 0.206
APRI 0.971 (0.718–1.314) 0.85
FIB4 0.926 (0.842–1.02) 0.12
Lok index 0.722 (0.154–3.386) 0.68
P2/MS 1.004 (0.998–1.01) 0.179
Abbreviations: OR odds ratio, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, HBV hepatitis B virus, HCV hepatitis C virus,
BCLC Barcelona Clinic Liver Cancer, MELD model for end-stage liver disease, INR international normalized ratio, AFP alpha-fetoprotein, PIVKA-II protein induced by
vitamin K absence-II, Ang2 angiopoietin-2, bFGF basic fibroblast growth factor, HGF hepatocyte growth factor, LOXL2 lysyl oxidase-like 2, PDGFRb platelet-derived
growth factor receptor β, sVEGFR1 soluble vascular endothelial growth factor receptor-1, AAR aspartate aminotransferase/alanine aminotransferase ratio, APRI
aspartate aminotransferase to platelet ratio index, FIB-4 fibrosis 4
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the prediction model was also verified with internal
validation.
Since the approval of sorafenib in 2007, no clinical
trial with newer agents has shown superior outcomes as
a first-line treatment, until recently [8]. More importantly,
there is no predictive biomarker for the selection of pa-
tients who could benefit most from sorafenib, unlike other
malignancies including breast cancer, lung cancer, and
melanoma [24–26]. Most of the prospective clinical trials
of molecular targeted therapies in patients with HCC to
date were not designed for a prespecified patient popula-
tion based on molecular classification and biomarkers. In
addition, because noninvasive diagnosis is feasible in most
cases with the characteristic imaging features, this
omission of obtaining tumor tissue is another obstacle for
biomarker exploration in HCC [12]. Thus, we explored
candidate biomarkers for the prediction of sorafenib
response in a prospectively collected clinical database and
serum samples from an in-hospital cohort.
Comparing the present study with the Asia-Pacific
sorafenib study [5], the median time to progression
(2.7 months) was similar; however, the median OS
(11.2 months) was longer in the present study than in the
Asia-Pacific study (6.5 months). Although most of the en-
rolled patients had chronic hepatitis B in both studies,
Table 3 Scoring system for the prediction of sorafenib response
by using six covariates selected in the multivariable binary
logistic regression analysis
Variable Cutoff value Score
bFGF (pg/mL) < 2.0 0
2–5.5 1
≥5.5 2
Log PIVKA-II (mAU/mL) < 30 0
30–1780 1
≥1780 2





Log HGF (pg/mL) < 1380 0
1380–1860 1
≥1860 2
Platelet (×103/μL) < 70 0
70–184 1
≥184 2
Abbreviations: bFGF basic fibroblast growth factor, PIVKA-II protein induced
by vitamin K absence-II, BCLC Barcelona Clinic Liver Cancer, HGF hepatocyte
growth factor
Fig. 1 Area under the receiver-operating curve (AUC) analysis for exploring a threshold score for predicting sorafenib response. The risk score was
calculated by using six covariates from the multivariable binary logistic regression analysis (Table 3). When the score was 6 or higher, the sorafenib
response was expected to be progressive disease with maximal sensitivity and specificity
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patients in the Asia-Pacific study had more advanced tu-
mors in that macrovascular invasion or extrahepatic
spread was more frequently observed, which might have
been responsible for the difference in OS. Indeed, a suba-
nalysis of the GIDEON study from Japan reported that the
median OS duration of patients with sorafenib therapy
was 17.4 months in those with Child-Pugh class A disease
and 4.9 months in those with Child-Pugh class B [27].
The longer OS in Japanese patients with Child-Pugh class
A might have resulted from the inclusion of fewer patients
in BCLC stage C, compared with our study population
(54.7 vs. 66.9%).
The selected covariates for the prediction of sorafenib
response from the logistic regression analysis included
etiology (B-viral), platelet count, BCLC stage, PIVKA-II,
serum bFGF, and serum HGF. Concerning the etiology,
hepatitis B-associated HCC was suggested as one of the
possible reasons for the shorter OS in the Asia-Pacific
study than that in the SHARP study [5]. High serum
PIVKA-II level has been reported as a significant predis-
posing factor for aggressive HCC biology including vas-
cular invasion, intrahepatic spread, and extrahepatic
spread [28–30]. Among serum angiogenic factors, bFGF
and HGF were selected as covariates in the final risk
scoring model. FGF2 or bFGF is known to stimulate
HCC proliferation through an autocrine mechanism, to
activate HCC invasion, and to induce angiogenesis [15].
Fig. 2 Kaplan-Meier survival curves for subgroups according to the risk scores. The median overall survivals were 19.0 months in group A (score≤ 5,
solid black line), 11.2 months in group B (score 6, dashed line), and 6.1 months in group C (score≥ 7, dotted line) (P < 0.001, log-rank test)
Table 4 Cox proportional hazards analysis for predicting
survival in the subgroups according to risk scores
Risk group HR (95% CI) P
Intermediate risk vs. low risk 2.529 (1.120–5.707) 0.025
High risk vs. low risk 6.577 (3.419–12.655) < 0.001
Risk groups according to risk scores: low-risk group, score ≤ 5; intermediate-
risk group, score 6; high-risk group C, score ≥ 7
Abbreviations: HR hazard ratio, CI confidence interval
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In addition, previous studies reported that bFGF level in-
creased as the tumor stage became more advanced, and
was predictive of worse postoperative survival in patients
with HCC [31, 32]. HGF/MET (mesenchymal-epithelial
transition) factor is frequently dysregulated, playing a
pivotal role in malignancies, including HCC [33]. Activa-
tion of the c-MET pathway promotes tumor cell growth,
angiogenesis, and metastasis, leading to more aggressive
forms of HCC and poor outcomes [34]. A scoring
system was developed by combining all the above-
mentioned covariates, which showed good predictive
performance for sorafenib response (area under the
receiver-operating curve of 0.884 at the cutoff score of
6). More desirably, when patients were stratified into
three subgroups according to risk scores, OS of the
high-risk group was significantly shorter than that of the
low-risk group. Recent clinical trials have investigated
the efficacy of newer molecular targeted agents in ad-
vanced HCC, such as tivantinib (NCT01755767) and
lenvatinib (NCT01761266). Tivantinib is an HGF/c-
MET inhibitor, and lenvatinib is a multitargeted receptor
kinase inhibitor against VEGFR 1, 2, and 3; fibroblast
growth factor receptor 1, 2, 3, and 4; platelet-derived
growth factor receptor; RET; and c-KIT [33, 35]. Given
that the signaling pathways of these new agents do not
entirely overlap with the targets of sorafenib, the rele-
vance of HGF and bFGF in the prediction of the re-
sponse to and the outcome of sorafenib therapy suggests
the possibility of an individualized approach in the selec-
tion of systemic agents in this difficult-to-treat popula-
tion, based on the prediction model in the present study.
Lastly, platelets are the source of multiple growth factors
and cytokines, and are known to promote tumor growth,
angiogenesis, and metastatic potential [36–38]. Several
reports have provided evidence supporting the role of
platelets in HCC, e.g., reduction of hepatitis B virus–as-
sociated experimental HCC by platelet inhibitors [39],
antagonism of sorafenib action by platelet factors in
HCC cell lines [40], and complete remission of advanced
HCC with sorafenib in combination with clopidogrel
[41]. Taken together, platelet count was also included in
the final risk prediction model in the present study;
however, its precise role in molecular targeted therapy
needs more investigation.
The results and the risk scoring system of our study
need to be interpreted and applied with caution owing
to the following limitations. Firstly and most import-
antly, although the samples for various biomarker assays
were archived in a prospective cohort, multiple use of
statistical algorithms raises concerns about false-positive
results or overfitting [42, 43]. The most desirable setting
to avoid these concerns would be a prospective trial that
focuses on a specific (group of ) biomarker(s) [42]. How-
ever, exploration of predictive biomarkers for sorafenib
response in a new trial is not logistically feasible, except
for large-scale comparative studies with newer agents
[44]. Thus, we chose a retrospective analysis as an alter-
native approach using prospectively collected samples.
Secondly, a split-sample method for the validation of the
results could not be applied in our cohort owing to the
limited number of study subjects [45]. Instead, we per-
formed internal validation using 3-fold cross-validation.
An external validation with consistent results is a pre-
requisite for the application of this scoring system in
other patient populations with a larger sample size [42].
Finally, differences in the baseline clinical characteristics
of the study subjects also hinder the imprudent
generalization of our results in patient populations with
a different etiology or tumor status.
Conclusions
In conclusion, we developed a biomarker-based predic-
tion model of sorafenib response and survival from a
prospective cohort. By using baseline serum bFGF and
HGF levels as covariates, a total score of < 6 could be a
relevant cutoff value for selecting patients who are most
likely to benefit from sorafenib therapy. Furthermore,
the cutoff value may also be used as guide to avoid un-
necessary toxicity and inconvenience in patients with a
score above this cutoff.
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